NFKB1 and Miyoshi myopathy: Broad effects have been reported after PI treatment in MM (e.g., blockade of NF-κB activation, cell cycle arrest, intrinsic and extrinsic induction of apoptosis, inhibition of DNA repair enzymes, and the inhibition of adhesion of myeloma and bone marrow stromal cells) (reviewed in [25,26,27]), which likely contributes to the clinical efficacy of these agents in MM.